Biomarker Testing in Non-Small Cell Lung Cancer
Biomarker testing is recommended for many patients with metastatic non-small cell lung cancer (NSCLC), because testing can identify which patients are eligible for targeted therapy or immunotherapy. Patients who are treated with targeted therapies or immunotherapies have better outcomes and fewer adverse events compared with those receiving traditional cytotoxic chemotherapy regimens. New targeted therapy and immunotherapy regimens are frequently approved and added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer. Newer testing methods are being developed for patients who are not medically fit for invasive testing. Oncologists should be familiar with the current biomarker testing recommendations to improve outcomes for their patients with metastatic NSCLC.
This educational program is designed to meet the educational needs of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, pharmacists, physician assistants, and other relevant health care professionals who manage the care of patients with lung cancer.
Following this activity, participants should be able to:
- Review new recommendations for biomarker testing to improve outcomes of patients with metastatic non small cell lung cancer.
- Discuss recommended biomarker testing methodologies for patients with metastatic non small cell lung cancer.
- Determine when it is appropriate to use liquid biopsies to guide treatment selection.
Dara L. Aisner, MD, PhD
University of Colorado Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses the following relevant financial relationships:
Dara L. Aisner, MD, PhD
Bayer HealthCare: Consulting Fee
Genentech, Inc.: Grant/Research Support
Loxo Pharmaceuticals: Consulting Fee
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson;
Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Sarah Sinclair;
Kathy Ann Smith, CHCP
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Jennifer L. Burns, BS; Susan D. Darlow, PhD; Miranda Hughes, PhD; Alyse Johnson-Chilla;
Ann Karosas, RPh, BCOP; Rashmi Kumar, PhD; Jillian Scavone, PhD (employed by NCCN until 7.26.19)
The NCCN Clinical staff listed below discloses the following relevant financial relationships:
Griselda Zuccarino-Catania, PhD
Janssen Pharmaceutica Products, LP: Spouse Salary
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 0.87 contact hours.
NCCN designates this knowledge-based continuing education activity for 0.75 contact hours (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-19-106-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 12/17/2020. PAs should only claim credit commensurate with the extent of their participation.
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.87 ANCC contact hours
- 0.75 Participation
To complete this activity, users will need:
- A device with an Internet connection
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari (Internet Explorer is no longer supported)
- Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
- Adobe Reader or other PDF reader software for certificate viewing/printing